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Abstract
Background: The ACCESS programme aims at understanding and improving access to prompt and effective malaria 
treatment. Between 2004 and 2008 the programme implemented a social marketing campaign for improved 
treatment-seeking. To improve access to treatment in the private retail sector a new class of outlets known as 
accredited drug dispensing outlets (ADDO) was created in Tanzania in 2006. Tanzania changed its first-line treatment 
for malaria from sulphadoxine-pyrimethamine (SP) to artemether-lumefantrine (ALu) in 2007 and subsidized ALu was 
made available in both health facilities and ADDOs. The effect of these interventions on understanding and treatment 
of malaria was studied in rural Tanzania. The data also enabled an investigation of the determinants of access to 
treatment.
Methods: Three treatment-seeking surveys were conducted in 2004, 2006 and 2008 in the rural areas of the Ifakara 
demographic surveillance system (DSS) and in Ifakara town. Each survey included approximately 150 people who had 
suffered a fever case in the previous 14 days.
Results: Treatment-seeking and awareness of malaria was already high at baseline, but various improvements were 
seen between 2004 and 2008, namely: better understanding causes of malaria (from 62% to 84%); an increase in health 
facility attendance as first treatment option for patients older than five years (27% to 52%); higher treatment coverage 
with anti-malarials (86% to 96%) and more timely use of anti-malarials (80% to 93-97% treatments taken within 24 hrs). 
Unfortunately, the change of treatment policy led to a low availability of ALu in the private sector and, therefore, to a 
drop in the proportion of patients taking a recommended malaria treatment (85% to 53%). The availability of outlets 
(health facilities or drug shops) is the most important determinant of whether patients receive prompt and effective 
treatment, whereas affordability and accessibility contribute to a lesser extent.
Conclusions: An integrated approach aimed at improving understanding and treatment of malaria has led to tangible 
improvements in terms of people's actions for the treatment of malaria. However, progress was hindered by the low 
availability of the first-line treatment after the switch to ACT.
Background
The cornerstone of the World Health Organization's
malaria control strategy is prompt and effective treat-
ment for all episodes of malaria [1,2]. Largely thanks to
international support through the Global Fund to Fight
AIDS, Tuberculosis and Malaria (GFATM) and the World
Bank's Malaria Booster programme, most sub-Saharan
African countries have now switched to the highly effica-
cious artemisinin-combination therapy (ACT). Interna-
tional initiatives such as Medicines for Malaria Venture
(MMV) are increasingly speeding up the development of
new anti-malarials. However, the public health impact of
such drugs relies to a large extent on patient's ability to
access them and little progress will be made unless
broader access issues are tackled. Despite large increases
in the number of anti-malarial drugs supplied interna-
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tionally, surveys conducted between 2007 and 2008 in 11
African countries found that only 15% of fever cases were
treated with ACT [1].
Several strategies have been proposed and tested to
improve access to malaria treatment by targeting provid-
ers or users. Smith et al [3] recently conducted a system-
atic review of the effectiveness of various such
interventions in improving prompt and effective treat-
ment of malaria. Interventions reviewed included opti-
mizing case-management and services in health facilities
[4-8] or improving dispensing practices of drug shop
attendants and private practitioners [9-14] as well as
community based approaches [15-17]. Two general
approaches to improving user malaria treatment prac-
tices have been pursued: 1) health education campaigns;
[18,19] and 2) interventions that specifically provide
information on how to take anti-malarials [20], including
pre-packaging and pictorial and verbal instructions [21-
23]. The main finding from the review is that most inter-
ventions so far have been conducted on a rather small
scale and that few have been appropriately evaluated. As
a consequence, despite the wealth of research conducted
on the topic, little is known about interventions that can
promote sustained change.
The ACCESS programme in the Kilombero and Ulanga
D i s t r i c t s  i n  s o u t h - e a s t e r n  T a n z a n i a  a i m s  t o  i m p r o v e
understanding of and access to prompt and effective
malaria treatment through an integrated approach target-
ing both users and providers [24]. The programme's
activities are based on a conceptual framework, which
defines access as the degree of fit between the needs and
means of patients (users) and the existing services (pro-
viders) along the five dimensions of availability, accessi-
bility, affordability, adequacy and acceptability [25].
Interventions are carried out at three levels: 1) the com-
munity; 2) the formal health sector; and 3) the private
retail sector for drugs. A comprehensive monitoring and
evaluation plan accompanied each of these interventions.
The implementation of the programme started in 2004
and the second phase will be completed in 2011
Between 2004 and 2007 the ACCESS programme's
main intervention at community level was a social mar-
keting campaign for improved recognition of the disease
and more effective care-seeking. It followed on the work
by the KINET project which used a social marketing
approach to promote the use of insecticide treated nets in
the same area [26]. Various communication channels
were used and material developed to disseminate infor-
mation on malaria transmission, symptoms and preven-
tion as well as to stress the importance of prompt and
effective treatment. Road shows were the main activity
and included role-plays, public lectures and quizzes. In
addition, promotional materials (e.g. stickers, leaflets, t-
shirts) were distributed, and billboards and posters dis-
played in public places. The programme also organized
special campaigns targeted at pregnant women and
mothers of young children in mother and child health
(MCH) clinics. Social marketing campaigns were con-
ducted in 96% (78/81) of the villages in the Kilombero
District and 95% (62/65) of the villages in the Ulanga Dis-
trict. More detailed information on the ACCESS social
marketing campaigns can be found elsewhere [24].
The ACCESS programme also intervened in the public
health sector to improve quality of care. Key activities
included strengthening of routine supervision and
refresher training for health facility staff based on inte-
grated management of childhood illness (IMCI) Algo-
rithms [24]. In 2004 and 2005, 91% (94/103) of all health
workers in the Ulanga District and 93% (39/42) of clinical
officers in the Kilombero District attended a refresher
training. In addition, the study period saw the change of
the first line treatment for malaria. In 2006 the Govern-
m e n t  o f  T a n z a n i a  s w i t c h e d  f r o m  s u l p h a d o x i n e
pyrimethamine (SP) to artemether-lumefantrine (ALu).
Actual introduction of ALu in health facilities was
delayed until 2007, with resulting stock-outs in the transi-
tion period [27].
In parallel, the accredited drug dispensing outlets
(ADDOs) programme was rolled out in the study area
from 2006 onwards to improve access to treatment and
quality of care in the private drug retail sector [28].
ACCESS undertook the local evaluation and monitoring
of the programme. The private retail sector plays a very
important role in the delivery of anti-malarial treatment
in most African countries, as retailers tend to be more
accessible and flexible, especially with regards to opening
hours and charges [29,30]. The aim of the ADDO pro-
gramme is to improve access to basic medicines by
upgrading all existing drug shops to well regulated and
properly operated outlets manned by specifically trained
personnel [31]. The intervention involved a combination
of private drug shop dispenser training, incentives,
accreditation and regulation. The ADDO programme
greatly improved the availability and accessibility of drug
shops and, most importantly the quality of advice and
dispensing [27] (Dillip et al., unpublished data). ALu was
made available to the programme at a highly subsidised
price towards the end of 2007, but this did not result in
widespread availability of the drug, allegedly because of
low profit margins on the drug and long distances to the
wholesalers. Between 2006 and 2008, 55 ADDOs were
opened in the Ulanga District and 135 in the Kilombero
District (equivalent to approximately three shops per
10,000 people in both districts).
The primary aim of this study was to evaluate changes
in understanding and treatment-seeking for malaria in
the Kilombero and Ulanga Districts during the period
2004-2008 and to assess how such changes could beAlba et al. Malaria Journal 2010, 9:163
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attributed to the three interventions evaluated by the
ACCESS programme. The results presented here are
complemented by a study, which focused on changes in
availability, accessibility and affordability of treatment
over the same period (i.e. the provider perspective) [27].
The data also provided a unique opportunity to apply a
recent analytical framework on access to treatment [25]
in a real-life situation and to assess the determinants of
access to prompt and effective treatment.
Methods
Study setting
The study was carried out in the rural areas of the Kilo-
mbero and Ulanga Demographic Surveillance System
(DSS) and in the semi-urban setting of Ifakara town
between 2004 and 2008 (Figure 1). In the rural DSS area
every household is visited every four months to collect a
set of basic demographic data. As a result, a comprehen-
sive and continuously updated database of the resident
population is maintained for the study area. The rural
DSS covers 25 villages (13 in Kilombero and 12 in
Ulanga). The population in 2004 was almost 74,000 and
just over 92,000 in 2008. The population of Ifakara town
was 45,700 according to the national census of 2002 [32].
A study conducted in the area between 2001 and 2003
reported an Entomological Inoculation Rate (EIR) of 349
infective bites per person per year (ib/p/y) [33], but
according to recent data it has declined to 81 ib/p/y (Rus-
sell et al., unpublished data). EIR data for Ifakara town
suggest that the transmission rate is about a log order
smaller than in the surrounding rural areas [34]. The area
has been described in more detail elsewhere [24,35].
The formal health sector
There are six health facilities in the rural Kilombero DSS
area and eight health facilities in the Ulanga DSS area.
The Designated District Hospital in Ifakara serves as a
referral centre for the entire area and there are also two
other health facilities in town. Government and faith-
Figure 1 Map of Kilombero and Ulanga Districts showing Ifakara Town and the Demographic Surveillance System (DSS).Alba et al. Malaria Journal 2010, 9:163
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based facilities in Kilombero and Ulanga charge user fees.
In the Ulanga District the Community Health Fund
(CHF) offers a form of risk protection to its members but
very few people were enrolled during the study period
(around 3% of the population in 2005 - personal commu-
nication from the District Medical Officer). Children
under five years of age, pregnant women and elderly peo-
ple should receive services and drugs free of charge, but
there is ample evidence that the exemption mechanism is
not properly implemented [36,37].
Retail sector for drugs
By 2008 90% (49/54) of drug shops in the study area were
ADDOs. Between 2004 and 2008 the number of shops
per 1000 people increased from 0.24 to 0.39 and as a
result the proportion of people living within 5 km from a
shop increased from 71% in 2004 to 87% in 2008. The roll
out of ADDOs coincided with a stark decrease in the
availability of anti-malarial drugs in non-licensed general
shops. Mystery shopper surveys showed that the propor-
tion of customers with malaria symptoms who got cor-
rect advice and treatment in drug shops increased from
just above 30% to nearly 80% between 2004 and 2008
(Dillip et al., unpublished data) after the introduction of
ADDOs. Although ALu was made available in ADDOs in
mid 2007 with a high level of subsidy by 2008 it was only
stocked by a third of shops. SP and other older anti-
malarials remained much more widely available and sold
[27].
Treatment-seeking surveys
Three cross sectional surveys were conducted in the rural
DSS areas and Ifakara town in 2004, 2006 and 2008 to
investigate treatment-seeking for malaria and under-
standing of the disease. The interviewees included chil-
dren and adults who had recently suffered a fever episode
(caretakers responded to questions for children under the
age of 12). Data collection was carried out every other
year between May and August, a time of the year which
coincides with the dry season and is characterised by a
lower intensity of transmission. An analysis of the base-
line study in 2004 was published by Hetzel et al [37] and
the results presented here provide a longitudinal assess-
ment of the changes between 2004 and 2008.
Sampling procedure
Different sampling procedures were applied in the rural
DSS area and in Ifakara Town. In the DSS area, a village-
stratified random sample of households was drawn from
the existing comprehensive DSS register. Only house-
holds with at least one child under the age of five years
were eligible. In Ifakara such a sampling frame was not
available. Therefore, the local administrative structure
was used to draw a two-stage random sample of house-
holds, using ten-cell leaders (balozi) as first level of sam-
pling. Given a background of decreasing fever incidence
rates (Alba et al., in preparation), every year a greater
n u m b e r  o f  h o u s e h o l d s  w e r e  s a m p l e d  t o  e n s u r e  t h a t
approximately 150 fever cases could be followed up
(Table 1). All individuals from the sampled households
who reported an episode of fever within the previous 14
days were included in the study . Patients who had not
recovered clinically were not included and they were
instead advised to seek care from a health facility. More
details on the sampling and interviewing procedure can
be found in the baseline paper [37]
Data collection tool
The tool for data collection was a locally adapted Explan-
atory Model Interview Catalogue (EMIC) [38] based on
focus group discussions and prior research carried out in
the study area [39,40]. This semi-structured question-
naire provides qualitative and quantitative data on
patients' signs and symptoms associated with the fever
episode (patterns of distress), as well as perceived causes
and treatment-seeking. Patients were also asked to label
the disease according to their own understanding. In the
study area most cases were labelled as malaria, homa
(fever) and degedege (fever-related disease with neurolog-
ical involvement [40]).
Distance from households to nearest point of care
Distances from households to the nearest health facility
or drug shop were calculated by combining the global
Table 1: Sample size and number of fever cases followed up in each survey round
DSS areas Ifakara Town
Households sampled 1 People interviewed Households sampled
(ten-cells × households per ten-cell)2
People interviewed
2004 318 110 223 (40 × 6) 44
2006 561 103 410 (50 × 9) 50
2008 750 86 739 (75 × 10) 41
1 Village-stratified sampling proportional to number of households per village
2 Two-stage sampling of households within ten-cells. The final number of households is lower than the product of the parts as some ten-cells 
have less than the chosen number of householdsAlba et al. Malaria Journal 2010, 9:163
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positioning system (GPS) locations of households from
the DSS database and the GPS positions of outlets
obtained from providers surveys [27]. The households
GPS values were available for 91% (100/110) households
in 2004, 97% (100/103) in 2006 and 87% (73/87) in 2008.
Measuring socio-economic status
A relative index of socioeconomic status (SES) was calcu-
lated for the households in the DSS villages using asset
ownership and household characteristics data stored in
the DSS database. A principal components analysis
(PCA) defined the weights of an SES index [41,42] for the
households in the survey, relative to all other households
in the area. Households were divided into five wealth
quintiles based on their SES score. The score was avail-
able for 97% (107/110) households in 2004, 93% (96/103)
in 2006 and 93% (81/87) in 2008. The variables included
in the analysis and the weight given to each is shown in
Table 2.
The variables collected for SES assessment in 2004 dif-
fered from the ones collected in subsequent years but this
was not considered to bias analyses. Comparing SES
quintile groupings in the DSS households showed similar
year on year comparability across all years in the poorest
and richest category. Indeed 40% (871/2157) of house-
holds categorised as poorest in 2004 were categorised as
poorest in 2006 and 47% (1256/2686) households cate-
gorised as richest in 2004 were categorised as richest in
2006. Similar, albeit higher values were found comparing
categories in 2006 and 2008, that is 53% (1341/2540) and
61% (1752/2882) respectively. As year on year compara-
bility in the three middle quintiles was poor, the middle
quintiles were grouped into one category which resulted
in 66% (4470/6813) of household categorised as middle in
2004 also categorised as middle in 2006 and similarly 73%
(5930/8104) comparing the 2006 and 2008 groupings.
With these regroupings it was assumed that the differ-
ence in the type of assets collected would not introduce
substantial bias.
Ethical clearance
All study participants provided oral informed consent
prior to the interview, the National Institute for Medical
Research of the United Republic of Tanzania granted eth-
ical clearance for the study (NIMR/HQ/R.8a/Vol.IX/236,
16th September 2003).
Analyses
Various indicators were constructed and compared
between 2004 and 2008. Indicators of understanding of
malaria focused on perceived causes and patterns of dis-
tress. Indicators of treatment included: actions, sources
and type of drugs used for the treatment of fever and
links of the community effectiveness chain based on the
approach developed by Hetzel et al [37]. The community
effectiveness chain breaks down the full Roll Back
Malaria (RBM) [2] indicator into its primary components
[43] and includes: the proportion of fever cases 1) treated;
2) treated with a drug; 3) treated with an anti-malarial; 4)
treated with a recommended anti-malarial; 5) treated
with a recommended anti-malarial on the same or next
day; 6) treated with a recommended anti-malarial the on
same or next day and following the correct regimen (cor-
rect number of tablets, timely intake and duration), i.e.
the full RBM indicator; 7) treated with a recommended
anti-malarial on the same or next day, following the cor-
rect regimen and appropriately considering reported
symptoms (with quinine if symptoms of severe malaria
are reported). Since the change of treatment policy only
effectively took place one year before the last 2008 survey,
two scenarios were presented for 2008. The first scenario
is strictly according to guidelines, following which only
ALu qualifies as a recommended treatment, whereas the
second scenario also allows for SP as a recommended
treatment. Logistic regressions estimated the effect of
changes over time from 2004 to 2008 with time entered in
the model as a categorical variable. Estimates of change
over time were reported crude as well as adjusted by SES
groupings since SES score was higher in the last two sur-
veys compared to the first survey.
The recently developed access to treatment framework
[25] was applied to the data to estimate the determinants
of access in the study area. The framework defines five
dimensions of access, namely availability, accessibility,
affordability, adequacy and acceptability. Availability
refers to the existence of appropriate service. Thus, an
indicator of availability was defined as the presence of an
outlet (health facility or drug shop) stocking anti-malarial
drugs in the village of residence of the patient. Accessibil-
ity refers to the geographical distance between the ser-
vices and the homes of intended users. The main
indicator of accessibility was thus defined as the distance
from the patient's main residence to the nearest outlet
stocking anti-malarials (health facility or drug shop). But
since patients in the study area often spend a significant
amount of time in farming fields far away from house-
holds and outlets [44], a secondary indicator of accessibil-
ity was defined as whether the patients were in their main
r e s i d e n c e  o r  a w a y  i n  f a r m i n g  f i e l d s  a t  o n s e t  o f  f e v e r .
Affordability refers to whether the prices of services fit
the patients' income and ability to pay. The patient's SES
quintile was taken as a surrogate indicator for income and
how much they spent on their treatment (drug and con-
sultation) as an indicator of their ability to pay. The data
necessary to construct indicators of acceptability and
adequacy were not available. The analysis only included
patients from the rural DSS villages as data on SES and
distances to nearest shop or health facility were not avail-
able for households in Ifakara town. Univariate logistic
regressions assessed contribution of each of the accessAlba et al. Malaria Journal 2010, 9:163
http://www.malariajournal.com/content/9/1/163
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Table 2: Results of principal components analysis of socio-economic status (SES) variables
Item 2004 2006 2008
Mean weight Mean weight Mean weight
Meals consumed per day in past 2 days 2.31 0.42
Days per week that the following is consumed:
Meat 0.71 0.29
Rice 3.92 0.23
Tea 2.37 0.42
Main source of food:
Market 0.52 -0.34
Own farm 0.44 0.37
Source of water: 1 = tap 2 = well with pump 3 = well 4 = river 2.49 -0.06
Household owns at least 1:
Bicycle 0.45 0.32 0.57 0.42 0.65 0.44
Radio 0.49 0.34 0.65 0.38 0.66 0.42
Animal 0.09 0.17 0.10 0.23
Mobile phone 0.07 0.28 0.28 0.42
Corrugated iron roof 0.32 0.35 0.34 0.34
Small business as source of income 0.09 0.09 0.11 0.13
Rented accommodation 0.10 -0.02 0.10 0.02
Number of mosquito nets 1.97 0.46 2.03 0.35
Number of rooms 2.09 0.17 2.18 0.45 2.23 0.38
Toilet or latrine 0.92 0.15 0.93 0.06
Number of households included 14515/14997 16762/16888 17764/18813
Variation explained by first principal component 24% 23% 24%
indicators on the odds of the patient receiving of prompt
and effective treatment within 24 hours. A multivariate
model was built (by backward elimination of variables
with a log-likelihood ratio test greater than 0.2) to assess
the relative contribution of each of the access indicators.
Epi Info 6 and Intercooled Stata 9 (College Station,
Texas, USA) were used for random sampling procedures.
D a t a  w e r e  d o u b l e  e n t e r e d  i n  M i c r o s o f t  F o x P r o  a n d
Microsoft Access (Microsoft Corp.) and checked for cod-
ing errors and consistency. Statistical analysis was done
with Intercooled Stata 9. Distance calculations were car-
ried out with ArcMap Version 9.1 (ESRI Inc.)
Results
The cross-sectional samples were similar over the three
years of observation in terms of age, sex, residence, reli-
gion and years of formal education. Despite being mar-
ginally wealthier, households in 2008 were located further
away from drug shops and health facilities (Table 3).
Understanding of malaria
The population appears to be more aware of malaria, its
causes and its prevention in 2008 compared to 2004 (Fig-
ure 2). While in 2004 57% (80/137) of people labelled
their fever case as malaria, the proportion rose to 80%
(102/127) in 2008 (crude OR = 3.14 p < 0.001, adjusted
for SES OR = 2.31 p = 0.008). The proportion of cases
labelled malaria attributed to mosquito bites significantly
increased from 62% (79/127) to 84% (97/116) (crude OR
= 3.10 p < 0.001, adjusted for SES OR = 2.02 p = 0.056).
The proportion of fever episodes with symptoms of con-
vulsions (twitching, stiff body, delirium, white eyes, kick-
ing limbs) labelled as malaria also consistently increased
from 57% (16/28) to 73% (8/11), although not signifi-
cantly so due to the small number of cases with such
symptoms (OR = 2.00 p = 0.373). The proportion of fever
cases believed to be preventable with the use of mosquito
nets did not increase, most likely because of the already
very high value of 81% at baseline.Alba et al. Malaria Journal 2010, 9:163
http://www.malariajournal.com/content/9/1/163
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Treatment of fever
There was no difference in health facility attendance and
treatment in children, but the proportion of older
patients who sought treatment in health facilities
increased significantly. Health facility attendance and
treatment was already very high at baseline in children
and did not change over the study period (health facility
attendance at some point during the illness 148/195 i.e.
76%; health facility attendance as first treatment action
119/201 i.e. 58%; treatment with anti-malarial from a
health facility 123/207 i.e. 59%). Conversely the odds of
older patients attending a health facility as a first treat-
ment option increased three-fold between 2004 and 2008
(from 20/73 i.e. 27% to 40/77 i.e. 52% OR = 2.9 p = 0.002)
unadjusted and nearly five-fold adjusting for SES (OR =
4.6 p = 0.001). The odds of older patients being treated in
a health facility also increased - not significantly (from
23/73 i.e. 32% to 33/77 i.e. 43% OR = 1.63 p = 0.152)
unadjusted but nearly three-fold adjusting for SES (OR =
2.9 p = 0.012).
The receipt of treatment from the private retail sector
increased over the study period. Overall the proportion
of cases treated with an anti-malarial from a drug shop
significantly increased from 31% (47/154) in 2004 to 31%
(47/153) in 2006 and 43% (54/127) in 2008 (OR = 1.68, p
= 0.038). Three points should be highlighted with regards
to this. Firstly, this effect is confounded by SES (adjusted
OR = 1.18 p = 0.632). The proportion mainly increased in
the three middle wealth quintiles from 19% (12/63) to
26% (12/46) and actually decreased in the poorest quin-
tile from 25% (5/20) to 20% (2/10) whereas it stayed stable
in the richest quintile (20/74 i.e. 27%). Secondly the
increase was mainly in patients over the age of five (38%
in 2004 to 52% in 2008) and not in children (25% in 2005
to 28% in 2008). Thirdly the increase in the use of the pri-
vate sector in patients older than five was due more to an
increase in people who attended health facilities and
obtained treatment from a shop (23/73 i.e. 31% in 2004 to
33/77 i.e. 43% in 2008) than in people who treated them-
selves directly from shops without ever visiting a health
facility (23/73 i.e. 32% in 2005 to 27/77 i.e 35% in 2008).
Few patients were treated from a general shop (30/434 i.e.
7%) (Table 4)
A breakdown of the types of anti-malarials taken also
shows some improvements over time although the low
uptake of ALu is disappointing (Figure 3). Treatment cov-
erage with anti-malarials is extremely high in the study
area. In 2004 the use of multiple anti-malarials to treat a
single fever case in children under the age of five was
common but it decreased in 2006 and 2008 (Figure 4).
The most commonly used drug over the study period was
SP. In 2008, more than a year after the change of treat-
ment policy, only 39% (48/124) of cases were treated with
ALu. The low uptake of ALu is partly explained by the
fact that even in health facilities not all cases received
ALu (only 63%) and partly because most of the people
who were treated in shops either received SP (65%), qui-
nine (20%) or amodiaquine (7%) and only 13% received
ALu (T able 4). Children were more likely to be treated
with the new drug than older patients but not signifi-
cantly so (23/50 i.e. 46% of children and vs. 23/77 i.e. 30%
older patients OR = 1.28 p = 0.439). Interestingly, patients
in the middle quintiles were the least likely to be treated
with ALu (poorest to middle quintiles OR = 3.56 p =
0.029, richest to middle quintiles OR = 3.15 p = 0.004)
Community effectiveness of malaria treatment
The comparison of the community effectiveness of
malaria treatment in 2004 and 2008 shows a clear
improvement over time (Figure 5). Despite a sharp fall in
the proportion of people taking a recommended treat-
ment for malaria after the switch to ALu, there were
appreciable improvements in terms of timeliness of treat-
ment. Comparing the number of people who took an
appropriate anti-malarial (indicator 4) and the number
who took it within 24 hours (indicator 5) shows that
whereas in 2004 80% (101/127) of were treated promptly,
in 2008 this figure rose to 97% (65/67) of patients who
took ALu or quinine (crude OR = 8.36 p = 0.005, adjusted
for SES OR = 6.39 p = 0.018), and 93% (113/122) of
patients who took a ALu, quinine or SP (crude OR = 3.23
p = 0.004, adjusted for SES OR = 4.23 p = 0.015).
The self-reported adherence to the recommended drug
regimen. only marginally improved. Adherence to SP
treatment regimens improved over time (55/72 i.e. 76% in
2004 vs. 41/49 i.e. 84% in 2008). However, just over two
thirds of patients completed their courses of ALu (22/32
i.e. 69%). Quinine treatments were always under-dosed
because the course was not taken for the full seven days
Overall, comparing the number of people who took an
appropriate anti-malarial within 24 hours (indicator 5)
and those who took it adhering full to its regimen (indica-
tor 6) shows that in 2004 32% (32/101) of timely treat-
ments were taken following regimen and in 2008,
although this figure rose to 51% (58/113) of patients who
took ALu, quinine or SP, only 31% (20/65) of patients who
took quinine or SP fully adhered to their regimen (strictly
according to guidelines: crude OR = 1.12 p = 0.809,
adjusted for SES OR = 0.94 p = 0.910; allowing for SP as
appropriate treatment in 2008: crude OR = 1.63 p = 0.212,
adjusted for SES OR = 1.40 p = 0.475).
There were some difference between adults and chil-
dren. Generally coverage was higher in children under
the age of five compared to the rest of the population.
The proportion of cases treated with a recommended
anti-malarial (including SP) within 24hrs increased from
73% (59/81) in 2004 to 88% (44/50) in 2008 in children
under the age of five (OR = 1.30, p = 0.030) and from 57%Alba et al. Malaria Journal 2010, 9:163
http://www.malariajournal.com/content/9/1/163
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Table 3: Sample characteristics
2004 2006 2008
N n (%)* N n (%)* N n (%)*
Age group 154 153 127
Under 5 years 81 (52.6%) 76 (49.7%) 50 (39.4%)
Over 5 years 73 (47.4%) 77 (50.3%) 77 (60.6%)
Sex 154 153 127
Male 71 (46.1%) 63 (41.2%) 54 (42.5%)
Female 83 (53.9%) 90 (58.8%) 73 (57.4%)
Residence 154 153 153
Ulanga DSS 61 (39.6%) 41 (26.8%) 40 (31.5%)
Kilombero DSS 49 (31.8%) 62 (40.5%) 46 (36.2%)
Ifakara 44 (28.6%) 50 (32.7%) 41 (32.3%)
Religion* 154 152 125
Muslim 63 (40.9%) 51 (33.5%) 50 (40.0%)
Christian 91 (59.1%) 101 (66.4%) 75 (60.0%)
Years of formal education** 137 150 125
< 7 years 56 (40.9%) 45 (30.0%) 38 (30.4%)
= 7 years 70 (51.1%) 99 (66.0%) 80 (64.0%)
> 7 year 11 (8.0%) 6 (4.0%) 7 (5.6%)
SES score *** 107 96 81
Poorest 20 (18.7%) 6 (6.3%) 10 (12.4%)
Middle 63 (58.9%) 62 (64.6%) 52 (64.2%)
Richest 24 (22.4%) 28 (29.2%) 19 (23.5%)
SES score ***
[mean (SD)]
107 0.09 (1.53) 96 0.41 (1.28) 81 0.44 (1.45)
Distance to nearest health facility (km) ***
[median (IQR)]
105 1.69 (2.74) 100 1.67 (3.43) 73 2.25 (3.83)
Distance to nearest Part II or ADDO drug shop (km) ***
[median (IQR)]
105 1.70 (4.13) 100 1.79 (3.30) 73 2.49 (1.94)
* unless otherwise stated
** of caretaker if patient < 12 years
*** DSS only (110 observations in 2004, 103 in 2006 and 86 in 2008)
(42/73) in 2004 to 90% (69/77) in patients over the age of
five (OR = 1.56 p < 0.001). The proportion of cases
treated with either ALu or quinine within 24hrs in 2008
was 72% (36/50) in children under the age of five and 38%
(29/77) in all other patients. However the proportion of
cases treated promptly and effectively and following the
recommended regimen tended to be slightly lower in
children under five than in adults. Allowing for SP the
proportion in children under five increased from 37%
(16/43) to 56% (19/34) and in adults from 28% (16/58) to
67% (39/58) between 2004 and 2008. Strictly according to
guidelines, i.e. excluding SP and conforming to the full
RBM indicator for prompt and effective treatment of
malaria, the figure in 2008 is 39% (13/33) for children and
12% (7/58) in adults.
Determinants of access
An analysis of the contribution of each of the access
dimensions suggests that the availability of anti-malari-
als, i.e. the presence of a drug outlet (health facility or
drug shop) in patients' village of residence, is the main
determinant of whether people get prompt and effective
treatment for malaria (Table 5). There was no significant
difference in promptness of treatment between patients
who had been treated in health facilities and those treated
in drug shop (OR = 1.28 p = 0.613), but patients treated in
drug shops were less likely to be treated with the appro-
priate drugs (OR = 0.14 p = 0.001). Patients living in vil-
lages with either a drug shop or a health facility were four
times as likely to get prompt and effective malaria treat-
ment than people from villages without outlets (OR =Alba et al. Malaria Journal 2010, 9:163
http://www.malariajournal.com/content/9/1/163
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Figure 2 Changes in understanding of malaria.
Table 4: Breakdown of types of anti-malarials received from each of the sources of treatment (number of cases and 
percentages)
2004 2006 2008
Health 
facilities
Drug 
shops
General 
shops
Health 
facilities
Drug 
shops
General 
shops
Health 
facilities
Drug 
shops
General 
shops
Chloroquine* 1
(2.1%)
Artemether-
Lumefantrine
40
(62.5%)
7
(13.0%)
1
(16.7%)
SP 40 (58.5%) 20 (42.6%) 10
(90.9%)
41 (51.2%) 33 (70.2%) 10
(83.3%)
11
(17.2%)
35
(64.8%)
3
(42.9%)
Amodiaquine 10 (14.7%) 9 (19.2%) 16
(20.0%)
9
(19.2%)
1
(8.3%)
4
(6.3%)
4
(7.4%)
Quinine 38 (55.9%) 26
(55.3%)
3
(27.3%)
24 (42.5%) 13 (27.7%) 3
(25%)
12
(18.8%)
11 (20.4%) 2
(28.5%)
T o t a l 6 84 81 18 04 71 26 45 4 6
* 2 patients took chloroquine in 2004 but information on source of treatment was available for 1 patientAlba et al. Malaria Journal 2010, 9:163
http://www.malariajournal.com/content/9/1/163
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4.10 p < 0.001 adjusting for differences in affordability
and accessibility). The presence of outlets influenced
promptness (OR = 5.83 p < 0.001) and appropriateness
(OR = 4.75 p < 0.001) of treatment to a similar extent.
Affordability contributed to a lesser extent to receipt
of treatment. Both the univariate and multivariate model
showed no difference in receipt of prompt and effective
treatment across socio-economic groups. However, peo-
ple who paid more for their treatment were more likely
receive it promptly and effectively (OR = 1.74 p = 0.008).
This implies that even poorer people manage to find the
resources to afford treatment. The cost of treatment
influenced the appropriateness of treatment (OR = 3.34 p
< 0.001) more than the timeliness (OR = 1.67 p = 0.017).
It is worth recalling here that a somewhat un-expected
pattern of ALu uptake was observed in 2008 whereby the
three middle quintiles were less likely to be treated with
ALu (cf. results in "Treatment of fever").
Accessibility is a determinant of access to treatment,
but only if people are in far away farms at onset of their
disease. People were twice as likely to be treated promptly
and effectively if they were residing in their main home-
stead rather than in the farming fields at the onset of their
fever (OR = 2.08 p = 0.032 in the multivariate model). The
location at onset of disease mainly influenced the receipt
of a recommended anti-malarial (OR = 2.48 p = 0.004)
rather than the timeliness of treatment (OR = 1.63 p =
0.133). However, if people were in their main homestead
at onset of disease, the distance to the nearest outlet did
not have a major impact on treatment provided the outlet
was present in their village (OR = 0.88 p = 0.082).
Discussion
The results presented here show improvements in under-
standing and treatment-seeking for malaria in two rural
districts in Tanzania after the implementation of the
ACCESS programme. Specific improvements include a
better understanding of the causes of malaria, an increase
in health facility attendance and treatment in patients
older than five years, and more timely use of anti-malari-
als. Unfortunately, the change of malaria treatment policy
from SP to ALu during the same period led to a lower
availability of the first line drug in the private retail sector.
As a consequence the proportion of patients taking a rec-
ommended malaria treatment dropped significantly in
2008.
Given the before-after nature of this study and the
absence of a control group it is difficult to attribute spe-
cific improvements to ACCESS interventions. However,
plausible explanations can be given on the basis of
accepted frameworks [45,46]. With this type of design
improvements are attributed to the programme if
Figure 3 Sources of treatment for fever and actions undertaken. Note HF = Health facility; AM = anti-malarial; HMM = home management of ma-
laria.Alba et al. Malaria Journal 2010, 9:163
http://www.malariajournal.com/content/9/1/163
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improvements are found in every step of the causal path-
way between intervention and outcomes and all other
explanations can be formally discarded. In this study the
main outcome of interest is prompt and effective treat-
ment and steps in the causal pathway include: 1) changes
in understanding of malaria; 2) changes in actions for the
treatment of malaria and; 3) changes in access outputs,
i.e. the accessibility, availability and affordability of treat-
ment, which were reported in a separate study [27].
It seems reasonable to credit the ACCESS social mar-
keting campaigns for part of the observed changes in the
understanding of malaria and the increased use of health
facilities as a first treatment action. Indeed, no other
efforts of this magnitude took place concurrently in the
area although there were some national campaigns on
both TV and radio, which stressed the importance of
prompt treatment for malaria. With regards to the lack of
increase in health facility attendance in children, it is
important to bear in mind that health facility attendance
in this age group was already very high for a rural African
s e t t i n g  w i t h  o v e r  7 5 %  o f  c h i l d r e n  v i s i t i n g  a  f a c i l i t y  a t
some point during their illness. The high level of action
already undertaken by mothers of small children at the
start of ACCESS is undoubtedly the result of a long-
standing effort in the area to improve comprehensively
malaria control parameters [26,47]. It is especially worthy
of note that increases in health facility attendance were
higher once adjusted for SES status. This would suggest
the ACCESS social marketing campaigns were able to
target even the less well off, which is far from always
being the case [48]. This result is consistent with data
from the evaluation of the Tanzania National Voucher
Scheme, which found that road shows are able to dissem-
inate messages more equitably than any other means of
communication such as radios and billboards (Hadji
Mponda, unpublished data).
The more timely use of anti-malarials can be attributed
to the combination of the ACCESS social marketing cam-
paigns and the ADDO intervention. On one hand the
ACCESS social marketing campaigns stressed the impor-
tance of prompt and effective treatment for malaria. On
the other hand following the ADDO intervention treat-
ment became more available and accessible [27]. The
good availability of ALu in health facilities in 2008, com-
Figure 4 Types of anti-malarials taken for treatment of fever. Note SP = sulphadoxine-pyrimethamine, AQ = amodiaquine, Qu = quinine, ALu = 
artemether-lumefantrine.Alba et al. Malaria Journal 2010, 9:163
http://www.malariajournal.com/content/9/1/163
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bined with the increase in health facility visits as a first
treatment action is likely to also have contributed to the
improved timeliness of treatment. It is worth highlighting
here two positive outcomes with regards to the role of
ADDOs and health facilities, which emerged from this
evaluation. Firstly self-treatment at home did not
increase significantly in neither children nor older
patients suggesting that ADDOs did not undermine the
role of the formal health sector, but rather complemented
it. Secondly, after the introduction of ADDOs, the pro-
portion of children who were taken to a health facility
and received an anti-malarial from a shop did not change
(10-12%), which refutes claims that health facility staff
refer patients to outlets in which they have a financial
stake. It is important the ADDOs continue to be ade-
quately supervised for these gains to be sustained.
The results presented here are largely compatible with
findings from the Smith et al. review [3], which con-
cluded that interventions involving private sector provid-
ers generally show a good impact. Similar to the Kilifi
Shopkeeper programme in Kenya [9,12] and other studies
targeting the private retail sector [10,13,14] (but contrary
to results by Winch et al. in Mali [16]), the ADDO pro-
gramme has achieved notable gains in terms of the qual-
ity of advice given by shopkeepers. Ignoring the
treatment policy change, the proportion of patients
treated promptly and effectively according to the recom-
mended regimen in both the private retail sector and the
public health sector increased from 32% to 63% in the
present study. This increase is comparable to the out-
comes in Kilifi (from 2% to 28% treated promptly and
effectively with the right dosage and duration) or in Mali
(from 2% to 42% treated effectively with the right dosage
and duration), which only targeted the private retail sec-
tor. However, this study has shown for the first time that
improvements can be sustained even at much higher lev-
els by focusing on both on the private and the public sec-
tor and that the 80% levels targeted by the RBM
Partnership are within reach [2].
The results presented here also confirm the reviewers'
conclusion that improving user practice is more challeng-
ing. Noticeable gains were made in terms of people's
actions for the treatment of fever (health facility atten-
dance for patients older than five years, timeliness of
Figure 5 Estimated effective coverage of fever treatment based on patients' or caretakers' accounts. Note: Percentages are the proportion of 
fever cases 1) treated; 2) treated with a drug; 3) treated with an anti-malarial; 4) treated with a recommended anti-malarial; 5) treated with a recom-
mended anti-malarial on the same or next day; 6) treated with a recommended anti-malarial on the same or next day and following the correct reg-
imen (correct number of tablets, timely intake and duration), i.e. the full RBM indicator; 7) treated with a recommended anti-malarial on the same or 
next day, following the correct regimen and appropriately considering reported symptoms (quinine if symptoms of severe malaria are reported).Alba et al. Malaria Journal 2010, 9:163
http://www.malariajournal.com/content/9/1/163
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treatment) but there was no clear improvement in the
proportion of cases following the recommended regimen
of anti-malarials. This appears to be the result of poor
patient adherence (mystery shopper surveys showed that
the proportion of customers with malaria symptoms who
got correct advice and treatment in drug shops increased
from just above 30% to nearly 80% between 2004 and
2008, Dillip et al, unpublished data). It is likely to be due
to the introduction of a new treatment (ALu) with a more
complicated regime than the previously recommended
SP combined with the absence of messages targeted at
users specifically focusing on the importance of adhering
to treatment regimens (although ALu was pre-packaged
with clear instructions and pictograms). Future social
marketing campaigns in the area should put more
emphasis on this component.
The community effectiveness chains show that treat-
ment coverage with anti-malarials is very high in the
study area, but the change of treatment policy led to a sig-
nificant drop in the proportion of patients taking a rec-
ommended malaria treatment. Despite high levels of ALu
stock in health facilities, the proportion of patients
treated with ALu remained low partly because the drug
was not widely available in drug shops. However, the
decrease in the proportion of patients treated strictly
according to guidelines should be seen in the light of the
fact that already in 2003 SP had a treatment efficacy of
50% [49], while upon its introduction ALu had a treat-
ment efficacy of more than 95% [50]. The low availability
of the first line drug in the private retail sector following
the change of treatment policy from SP to ALu, coupled
with the multiple stockouts of SP in public health facili-
ties during the treatment transition clearly indicate that
malaria treatment policy changes need to be considered
in a more comprehensive way. Fortunately, the availability
of ACT s in the commercial retail sector will be consid-
ered in Tanzania in 2010 in the frame of the Affordable
Medicine Facility for malaria [51].
Strategies to improve access to treatment should focus
especially on the availability of points of care. The pres-
ence of a health facility or drug shop in the village of resi-
dence was the strongest predictor of prompt and correct
treatment, whereas affordability (within the observed
range of prices) and accessibility indicators contributed
to a lesser extent. These results differ from those pre-
sented in a paper, which focused specifically on the farm-
ing season, and according to which fever cases which
occurred in the farming sites were as less likely to be
treated promptly and effectively as those which occurred
in the main homestead [44]. This discrepancy is probably
due to design issues (different populations and different
season). But the considerations from the analysis pre-
sented here are largely consistent with a qualitative study
on livelihood and health care which revealed that patients
Table 5: Determinants of receiving prompt and effective anti-malarial treatment according to current guidelines from 
either a health facility or a drug shop in the rural DSS villages between 2004 and 2008
Univariate model Multivariate model 
(n=264)
nO R
(95% CI) *
pO R
(95% CI) *
p
Availability Presence of outlet in the village of 
residence **
297 3.32
(1.96 to 5.63)
< 0.001 4.10
(2.17 to 7.73)
< 0.001
Affordability SES (baseline: middle quintiles) 282 0.951
Poorest 0.94
(0.44 to 2.03)
0.893
Richest 1.07
(0.59 to 1.95)
0.803
Cost of treatment *** (TSh1000) 297 1.73
(1.26 to 2.43)
0.002 1.74
(1.16 to 2.60)
0.008
Accessibility Distance household to nearest outlet ** 
(1 km)
276 0.84
(0.73 to 0.95)
0.006 0.88
(0.75 to 1.01)
0.082
Location at onset of fever (home vs. 
farming site)
295 1.83
(1.03 to 3.27)
0.039 2.08
(1.07 to 4.09)
0.032
* Adjusted for the effect of year of study
** Presence/distance to health facility for those treated in a health facility and presence/distance to drug shop for those treated in a drug shop
*** Drug + consultationAlba et al. Malaria Journal 2010, 9:163
http://www.malariajournal.com/content/9/1/163
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make considerable efforts to access treatment, including
walking long distances and selling important livelihood
assets [52]. Hence future interventions aimed specifically
at improving access to treatment should focus on extend-
ing the network of health facilities and ADDOs to under-
served villages and ensuring that drugs are available.
The main limitation of this study is the selection of
cases on the basis of reported fever only, since not every
fever case is due to malaria. Considering every fever as a
potential malaria case is consistent with the Integrated
Management of Childhood Illness (IMCI) guidelines for
treatment in areas of stable malaria [53]. This approach
was warranted when the survey was designed in 2003 and
the area experienced very high levels of transmission.
This is no longer justified in the study area since: 1)
recent data suggest a drastic change in the epidemiology
of malaria in the study area; and 2) a recent study piloting
the use of Rapid Diagnostic Tests for malaria (mRDT) in
local health facilities found that only 40% of fever cases
were actually due to malaria (D'Acremont et al. unpub-
lished data). It is difficult to assess how much the pres-
ence RDTs at the time of our surveys would have changed
our observations.
Another limitation concerns the variability observed in
the samples and the inconsistency of a finding with
another study conducted in the area. Despite a random
sampling from the comprehensive DSS database house-
holds in 2008 were located further away from health facil-
ities and drug shops despite an increase in the
accessibility of these outlets [27]. Furthermore the distri-
bution of patients across SES appeared to be unequal over
the years, with wealthier households over-represented in
the 2006 and 2008 samples. To account for differences in
SES across years all ORs of significant effects were
reported crude and adjusted for SES.
Finally, it is worth noting additional positive patterns of
treatment emerged from this analysis which were not
consistent with conclusions one might draw from the
provider survey conducted in the study area. Firstly, no
patient in Ifakara reported using an artemisinin mono-
therapy although they were available in 10-20% of shops
[27]. Secondly, the severe stockouts of SP, which were
reported by health facilities in the study area in 2006 did
not appear to have an impact on treatment since the pro-
portion of patients who obtained the drug did not
decrease as a result. The reason for this apparent paradox
is that availability data from health facilities is based on
end-of-month balance in the store-rooms. Hence, stocks
may be delivered at the beginning of the month and dis-
pensed in their entirety by the end of the month or drugs
may not be in the store-room but still present in the dis-
pensing room.
Conclusions
An integrated approach aimed at improving understand-
ing and treatment of malaria has led to tangible improve-
ments in terms of people's perception and actions for the
treatment of malaria. The positive results testify that
even in a poor and remote African setting, the Abuja tar-
gets for access to treatment can be achieved. A higher
impact on prompt and effective treatment according to
treatment guidelines was hindered by a change of treat-
ment policy, which led to low availability of the first-line
drug (ALu) in the private retail sector. This shows clearly
that ensuring consistent stocks of ALu in the private
retail sector is crucial to improve prompt and effective
treatment for malaria. Future interventions aimed at
improving access to treatment by targeting users should
have a focus on adherences to treatment regimens. Inter-
ventions targeting providers should aim at extending the
network of health facilities and ADDOs to underserved
villages.
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